Day 2 – Wednesday, 17 Sept 2025Wednesday, September 17, 2025 - ET (Eastern Time, GMT-05:00)

Major players in the tech space, with market caps orders of magnitude greater than traditional healthcare companies, are starting to make their move into the healthcare market. Could this transition provide a catalyst for growth within the healthcare sector? Our panel of big tech executives, and CEOs who have partnered with them, share their experiences from communicating and partnering with big tech.

• Strategies for engaging with big tech in the healthcare landscape
• How partnerships with big tech differ from traditional life science strategics
• Value provided by big tech to medtech companies

For medtech companies, reimbursement can prove the final hurdle before long-term commercial success. Yet, for many, the process is not considered early enough, leading to costly delays and additional investigations to prove value. Hear insights from CEOs, strategics and investors on successful reimbursement strategy among what may be a rapidly reformed CMS landscape.

• Potential for CMS reform and what it may mean
• Case studies in successful reimbursement strategy and the learnings newer companies can take
• Importance of considering reimbursement prior to regulatory approval

In today's digital age, the lines between commercial operations, R&D, and customer engagement are blurring. This panel explores how shared digital technologies can break down internal silos within pharma while simultaneously enhancing customer experiences. We'll discuss the strategic implementation of unified platforms, data-driven approaches, and seamless digital interactions to create a cohesive and patient-centric ecosystem.

• How can we break down the silos between Commercial & R&D for pharma success?
• Discussing how integrated data platforms and AI-powered analytics can facilitate faster decision-making and streamline the drug development process
• Exploring how shared digital tools can provide real-time market insights, patient feedback, and payer data to optimize product positioning and launch strategies
• Examining the importance of fostering a culture of cross-functional collaboration and digital literacy to ensure the successful implementation and adoption of shared technologies

Explore how pharmaceutical companies are leveraging generative AI to revolutionize omnichannel engagement. This panel will discuss how AI-driven analytics and technology are illuminating hidden insights in data, enabling hyper-personalization, and driving better health outcomes. Discover how pharma is orchestrating personalized communications and interactions that resonate with stakeholders at every stage of their journey.

• Understanding the evolution and the importance of a coordinated omnichannel approach in pharma marketing and communications
• Discussing how generative AI can rapidly produce tailored content, enhance field force training, and provide 24/7 support to HCPs and patients
• Exploring strategies to address challenges in AI implementation, fostering cross-functional collaboration, and ensuring data quality and ethical use

Founding a company is a daunting task, especially for first-time founders experiencing the highs and lows of entrepreneurship for the first time. We bring together investors and experienced medtech executives to discuss areas of commercialization which are often undervalued and neglected, and the value created by getting these aspects right.

• Areas which can often be overlooked by medtech founders
• The importance of having experience within the leadership team at a C-suite and board level
• Building for long-term success from day one

The USA has long been the first choice for life science commercialization, but where should companies go from there? With EUMDR creating uncertainty in Europe and increased interest in Asia and the Middle East, there is arguably more choice than ever before for global expansion. Our panel will delve in to the realities of global markets, strategies for getting there and how to know which market is best for your company.

• How to know when your company is ready for global expansion
• Finding partners and support in new markets
• Cultural and macroeconomic differences in different geographies and how they impact medtech

Medtech investment increased drastically between 2020 and 2021 in the height of the COVID-19 pandemic, riding the wave of increased investor interest and a wave of IPOs medtech valuations surged to unprecedented levels. These valuations naturally subsided through the lack of exits observed in the years since COVID, but with exits returning in the form of both IPOs and M&A investors are seeing real world examples of return on investments. Our panel of investors and medtech leaders discuss the future of valuations and expectations for investors and startups.

• The valuation correction and its impact
• What goes into a medtech company valuation
• Valuation expectations moving forward

Explore the transformative power of AI in Medical Affairs. This panel delves into how AI-driven insights are enhancing strategic decision-making, streamlining operations, and ultimately improving patient outcomes. Discover how Medical Affairs teams are leveraging AI to navigate the complexities of the digital landscape and deliver impactful results.

• How AI is enabling Medical Affairs teams to efficiently analyse vast amounts of data, identify key trends, and generate actionable insights
• Discussing how AI-powered tools are improving communication and collaboration with healthcare professionals, patients, and other stakeholders
• Exploring how AI-driven insights are informing key decisions in Medical Affairs, leading to more effective strategies and improved outcomes

Technologies like artificial intelligence (AI) and machine learning are now shaping the future of the life sciences industry – and data is the foundation that drives these technologies forward. However, without the right tools to help manage and process it, the best data in the world can quickly become useless.

• What are the biggest challenges to centralizing, standardizing, and managing data? How are pharma overcoming those challenges?
• What is the next frontier when it comes to data-driven solutions? What are the tools being developed right now that will transform the way we approach healthcare?
• What role does AI play in this? Where do you see the most potential for healthcare to benefit from the current AI tide?